Latest research on Prolia

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.

Prolia dosage

The recommended dose for XGEVA is 120 mg subcutaneously every four weeks, whereas for Prolia, it is 60 mg subcutaneous every six months. [source, 2014]
Prolia is not expected to cause such severe hypocalcemia due to the low dose at six-month intervals. [source, 2014]
Xgeva, on the other hand, might be expected to cause more hypocalcemia since it is given at a higher dose and more frequently. [source, 2014]
A dose of 120 mg Xgeva was administered subcutaneously every 4 weeks in the upper arm, with the serum calcium level monitored. [source, 2013]